Pasqualina Giordano
A5016180101- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Bone health and treatments
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
- Ovarian cancer diagnosis and treatment
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Breast Cancer Treatment Studies
- COVID-19 and healthcare impacts
- Cancer Mechanisms and Therapy
- Prostate Cancer Treatment and Research
- Medical Imaging and Pathology Studies
- Estrogen and related hormone effects
- Ferroptosis and cancer prognosis
- Histone Deacetylase Inhibitors Research
Centro di Riferimento Oncologico della Basilicata
2015-2017
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2017
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2010-2015
Weatherford College
2014
National Cancer Institute
2011-2012
Tumour Institute of Tuscany
2011
Ospedale San Paolo
1995
(1) The aim of our study is to evaluate the capacity Visually AcceSAble Rembrandt Images (VASARI) scoring system in discerning between different degrees glioma and Isocitrate Dehydrogenase (IDH) status predictions, with a possible application machine learning. (2) A retrospective was conducted on 126 patients gliomas (M/F = 75/51; mean age: 55.30), from which we obtained their histological grade molecular status. Each patient analyzed all 25 features VASARI, blinded by two residents three...
In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm data real-world setting.
Markers predictive of treatment effect might be useful to improve the patients with metastatic solid tumors. Particularly, early changes in tumor metabolism measured by PET/CT <sup>18</sup>F-FDG could predict efficacy better than standard dimensional Response Evaluation Criteria In Solid Tumors (RECIST) response. <b>Methods:</b> We performed evaluation before and after 1 cycle resectable liver metastases from colorectal cancer, within a phase 2 trial preoperative FOLFIRI plus bevacizumab....
Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a matter debate. The aim this study was to assess the feasibility and activity bevacizumab plus FOLFIRI in setting. Patients aged 18–75 years, PS 0–1, with liver-confined CRC were eligible. They received 5 mg kg−1 followed by irinotecan 180 m−2, leucovorin 200 5-fluorouracil 400 m−2 bolus 2400 46-h infusion, biweekly, for 7 cycles. Bevacizumab stopped at cycle 6. A single-stage, single-arm phase 2 design...
This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled 82 Italian centres, from October 2019 to January 2020. The primary endpoint was incidence influenza-like illness (ILI) until 30 April All ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, prospectively recorded all COVID-19...
The aim of this paper is to describe the time spent activate oncological non-profit clinical trials promoted in Italy by National Cancer Institute Naples, following implementation recent European laws.Data about process activation 5 multicentre were prospectively collected through a web-based system. impact guidelines was assessed comparing efficiency between applications started before and after decree introducing Clinical Trial Application form (MD-CTA). Outcomes descriptive analyses EC...
Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted practice and adaptations in management with solid tumors eligible receiving ICIs during pandemic, a special focus Campania region. Methods This survey (25 questions), promoted by young section SCITO (Società Campana di ImmunoTerapia...
Background: Immune-checkpoint inhibitors (ICIs) have increased and improved the treatment options for patients with non-oncogene-addicted advanced stage non-small cell lung cancer (NSCLC). However, role of ICIs in oncogene-addicted NSCLC is still debated. In this study, an attempt to fill informational gap on effect other driver mutations, we set out provide a molecular landscape clinically relevant oncogenic drivers programmed death-ligand 1 (PD-L1) positive patients. Methods: We...
Oncotherapy can shape intestinal microbiota, which, in turn, may influence therapy effectiveness. Furthermore, microbiome signatures during treatments be leveraged for the development of personalised therapeutic protocols cancer treatment based on identification microbiota profiles as prognostic tools. Here, first time, trajectory gut and salivary a patient treated with Larotrectinib, targeted approved diagnosed glioblastoma multiforme neurotrophic tyrosine receptor kinase (